Omega-3 polyunsaturated fatty acids in the brain: Metabolism and neuroprotection

Frontiers in Bioscience

Volumn 16, Issue 7, 2011, Pages 2653-2670

  Zhang, Wenting ^a   Li, Peiying ^a,b   Hu, Xiaoming ^b   Zhang, Feng ^b   Chen, Jun ^a,b   Gao, Yanqin ^a,c  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NONE   (China)

Author keywords

Alzheimer's disease; DHA; Ischemia; Parkinson's disease; Review

Indexed keywords

NEUROPROTECTIVE AGENT; OMEGA 3 FATTY ACID;

ACTIVE TRANSPORT; ALZHEIMER DISEASE; ANIMAL; BIOLOGICAL MODEL; BRAIN; BRAIN ISCHEMIA; DIET THERAPY; DRUG EFFECT; HUMAN; METABOLISM; PARKINSON DISEASE; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BRAIN; BRAIN ISCHEMIA; FATTY ACIDS, OMEGA-3; HUMANS; MODELS, NEUROLOGICAL; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 79959538376     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3878     Document Type: Article

References (171)

1. U. N. Das and L. G. Puskas: Transgenic fat-1 mouse as a model to study the pathophysiology of cardiovascular, neurological and psychiatric disorders. Lipids Health Dis, 8, 61 (2009)
2. J. X. Kang: Fat-1 transgenic mice: a new model for omega-3 research. Prostaglandins Leukot Essent Fatty Acids, 77(5-6), 263-7 (2007) (Pubitemid 350198864)
3. J. X. Kang, J. Wang, L. Wu and Z. B. Kang: Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature, 427(6974), 504 (2004) (Pubitemid 38209102)
4. M. Igarashi, J. C. DeMar, Jr., K. Ma, L. Chang, J. M. Bell and S. I. Rapoport: Docosahexaenoic acid synthesis from alpha-linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation. J Lipid Res, 48(5), 1150-8 (2007) (Pubitemid 46708682)
5. L. Lauritzen, H. S. Hansen, M. H. Jorgensen and K. F. Michaelsen: The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res, 40(1-2), 1-94 (2001) (Pubitemid 32008650)
6. M. Neuringer, G. J. Anderson and W. E. Connor: The essentiality of n-3 fatty acids for the development and function of the retina and brain. Annu Rev Nutr, 8, 517-41 (1988) (Pubitemid 19136337)
7. S. A. Moore, E. Yoder, S. Murphy, G. R. Dutton and A. A. Spector: Astrocytes, not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid (20:4 omega-6). J Neurochem, 56(2), 518-24 (1991) (Pubitemid 21901992)
8. T. L. Kaduce, Y. Chen, J. W. Hell and A. A. Spector: Docosahexaenoic acid synthesis from n-3 fatty acid precursors in rat hippocampal neurons. J Neurochem, 105(4), 1525-35 (2008) (Pubitemid 351590811)
9. S. A. Moore, E. Yoder and A. A. Spector: Role of the blood-brain barrier in the formation of long-chain omega-3 and omega-6 fatty acids from essential fatty acid precursors. J Neurochem, 55(2), 391-402 (1990)
10. S. A. Moore: Cerebral endothelium and astrocytes cooperate in supplying docosahexaenoic acid to neurons. Adv Exp Med Biol, 331, 229-33 (1993)
11. J. C. DeMar, Jr., H. J. Lee, K. Ma, L. Chang, J. M. Bell, S. I. Rapoport and R. P. Bazinet: Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats. Biochim Biophys Acta, 1761(9), 1050-9 (2006) (Pubitemid 44354290)
12. J. C. Demar, Jr., K. Ma, L. Chang, J. M. Bell and S. I. Rapoport: alpha-Linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid. J Neurochem, 94(4), 1063-76 (2005) (Pubitemid 41170593)
13. L. Peng, L. Gu, X. Hu, L. Zhao and L. Hertz: Complexity of depolarization-mediated ERK phosphorylation in cerebellar granule cells in primary cultures. Neurochem Res, 33(2), 328-35 (2008)
14. S. I. Rapoport and M. Igarashi: Can the rat liver maintain normal brain DHA metabolism in the absence of dietary DHA? Prostaglandins Leukot Essent Fatty Acids, 81(2-3), 119-23 (2009)
15. S. I. Rapoport, J. S. Rao and M. Igarashi: Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot Essent Fatty Acids, 77(5-6), 251-61 (2007) (Pubitemid 350214520)
16. J. M. Bourre, O. S. Dumont, M. J. Piciotti, G. A. Pascal and G. A. Durand: Dietary alpha-linolenic acid deficiency in adult rats for 7 months does not alter brain docosahexaenoic acid content, in contrast to liver, heart and testes. Biochim Biophys Acta, 1124(2), 119-22 (1992)
17. B. L. Scott and N. G. Bazan: Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc Natl Acad Sci U S A, 86(8), 2903-7 (1989) (Pubitemid 19112648)
18. T. Moriguchi, J. Loewke, M. Garrison, J. N. Catalan and N. Salem, Jr.: Reversal of docosahexaenoic acid deficiency in the rat brain, retina, liver, and serum. J Lipid Res, 42(3), 419-27 (2001) (Pubitemid 32270066)
19. M. Igarashi, F. Gao, H. W. Kim, K. Ma, J. M. Bell and S. I. Rapoport: Dietary n-6 PUFA deprivation for 15 weeks reduces arachidonic acid concentrations while increasing n-3 PUFA concentrations in organs of post-weaning male rats. Biochim Biophys Acta, 1791(2), 132-9 (2009)
20. A. Youyou, G. Durand, G. Pascal, M. Piciotti, O. Dumont and J. M. Bourre: Recovery of altered fatty acid composition induced by a diet devoid of n-3 fatty acids in myelin, synaptosomes, mitochondria, and microsomes of developing rat brain. J Neurochem, 46(1), 224-8 (1986) (Pubitemid 16185450)
21. J. M. Bourre, G. Pascal, G. Durand, M. Masson, O. Dumont and M. Piciotti: Alterations in the fatty acid composition of rat brain cells (neurons, astrocytes, and oligodendrocytes) and of subcellular fractions (myelin and synaptosomes) induced by a diet devoid of n-3 fatty acids. J Neurochem, 43(2), 342-8 (1984) (Pubitemid 14093559)
22. N. V. Eldho, S. E. Feller, S. Tristram-Nagle, I. V. Polozov and K. Gawrisch: Polyunsaturated docosahexaenoic vs docosapentaenoic acid-differences in lipid matrix properties from the loss of one double bond. J Am Chem Soc, 125(21), 6409-21 (2003) (Pubitemid 36605409)
23. R. C. Greiner, J. Winter, P. W. Nathanielsz and J. T. Brenna: Brain docosahexaenoate accretion in fetal baboons: bioequivalence of dietary alpha-linolenic and docosahexaenoic acids. Pediatr Res, 42(6), 826-34 (1997) (Pubitemid 27509543)
24. J. A. Hamilton and K. Brunaldi: A model for fatty acid transport into the brain. J Mol Neurosci, 33(1), 12-7 (2007) (Pubitemid 47574951)
25. W. Stremmel, L. Pohl, A. Ring and T. Herrmann: A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids, 36(9), 981-9 (2001) (Pubitemid 33065200)
26. C. T. Chen, Z. Liu, M. Ouellet, F. Calon and R. P. Bazinet: Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. Prostaglandins Leukot Essent Fatty Acids, 80(2-3), 157-63 (2009)
27. W. J. Lukiw and N. G. Bazan: Docosahexaenoic acid and the aging brain. J Nutr, 138(12), 2510-4 (2008)
28. C. C. Park and Z. Ahmed: Alterations of plasma membrane fatty acid composition modify the kinetics of Na+ current in cultured rat diencephalic neurons. Brain Res, 570(1-2), 75-84 (1992)
29. C. Bate, M. Tayebi, M. Salmona, L. Diomede and A. Williams: Polyunsaturated fatty acids protect against prionmediated synapse damage in vitro. Neurotox Res, 17(3), 203-14 (2010)
30. B. Grintal, G. Champeil-Potokar, M. Lavialle, S. Vancassel, S. Breton and I. Denis: Inhibition of astroglial glutamate transport by polyunsaturated fatty acids: evidence for a signalling role of docosahexaenoic acid. Neurochem Int, 54(8), 535-43 (2009)
31. W. Zhang, X. Hu, W. Yang, Y. Gao and J. Chen: Omega-3 polyunsaturated fatty acid supplementation confers longterm neuroprotection against neonatal hypoxic-ischemic brain injury through anti-inflammatory actions. Stroke, 41(10), 2341-7 (2010)
32. R. J. Deckelbaum, T. S. Worgall and T. Seo: n-3 fatty acids and gene expression. Am J Clin Nutr, 83(6 Suppl), 1520S-1525S (2006) (Pubitemid 44713093)
33. F. Zapata-Gonzalez, F. Rueda, J. Petriz, P. Domingo, F. Villarroya, J. Diaz-Delfin, M. A. de Madariaga and J. C. Domingo: Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR(gamma):RXR heterodimers: comparison with other polyunsaturated fatty acids. J Leukoc Biol, 84(4), 1172-82 (2008)
34. J. K. Virtanen, D. S. Siscovick, W. T. Longstreth, Jr., L. H. Kuller and D. Mozaffarian: Fish consumption and risk of subclinical brain abnormalities on MRI in older adults. Neurology, 71(6), 439-46 (2008)
35. L. Belayev, L. Khoutorova, K. D. Atkins and N. G. Bazan: Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia. Stroke, 40(9), 3121-6 (2009)
36. M. Okada, T. Amamoto, M. Tomonaga, A. Kawachi, K. Yazawa, K. Mine and M. Fujiwara: The chronic administration of docosahexaenoic acid reduces the spatial cognitive deficit following transient forebrain ischemia in rats. Neuroscience, 71(1), 17-25 (1996) (Pubitemid 26042868)
37. J. S. Fernandes, M. A. Mori, R. Ekuni, R. M. Oliveira and H. Milani: Long-term treatment with fish oil prevents memory impairments but not hippocampal damage in rats subjected to transient, global cerebral ischemia. Nutr Res, 28(11), 798-808 (2008)
38. Y. Goto, S. Okamoto, Y. Yonekawa, W. Taki, H. Kikuchi, H. Handa and M. Kito: Degradation of phospholipid molecular species during experimental cerebral ischemia in rats. Stroke, 19(6), 728-35 (1988)
39. K. Narita, M. Kubota, M. Nakane, S. Kitahara, T. Nakagomi, A. Tamura, H. Hisaki, H. Shimasaki and N. Ueta: Therapeutic time window in the penumbra during permanent focal ischemia in rats: changes of free fatty acids and glycerophospholipids. Neurol Res, 22(4), 393-400 (2000) (Pubitemid 30409597)
40. M. K. Baskaya, M. R. Prasad, D. Donaldson, Y. Hu, A. M. Rao and R. J. Dempsey: Enhanced accumulation of free fatty acids in experimental focal cerebral ischemia. Prostaglandins Leukot Essent Fatty Acids, 54(3), 167-71 (1996) (Pubitemid 26145303)
41. J. G. Pilitsis, F. G. Diaz, M. H. O'Regan and J. W. Phillis: Inhibition of Na(+)/Ca(2+) exchange by KB-R7943, a novel selective antagonist, attenuates phosphoethanolamine and free fatty acid efflux in rat cerebral cortex during ischemiareperfusion injury. Brain Res, 916(1-2), 192-8 (2001) (Pubitemid 32971920)
42. L. Belayev, V. L. Marcheselli, L. Khoutorova, E. B. Rodriguez de Turco, R. Busto, M. D. Ginsberg and N. G. Bazan: Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke, 36(1), 118-23 (2005) (Pubitemid 40054186)
43. E. B. Rodriguez de Turco, L. Belayev, Y. Liu, R. Busto, N. Parkins, N. G. Bazan and M. D. Ginsberg: Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J Neurochem, 83(3), 515-24 (2002) (Pubitemid 35231805)
44. M. Strokin, O. Chechneva, K. G. Reymann and G. Reiser: Neuroprotection of rat hippocampal slices exposed to oxygen-glucose deprivation by enrichment with docosahexaenoic acid and by inhibition of hydrolysis of docosahexaenoic acid-containing phospholipids by calcium independent phospholipase A2. Neuroscience, 140(2), 547-53 (2006)
45. M. Akbar and H. Y. Kim: Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis: involvement of phosphatidylinositol-3 kinase pathway. J Neurochem, 82(3), 655-65 (2002) (Pubitemid 34831503)
46. M. Akbar, F. Calderon, Z. Wen and H. Y. Kim: Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A, 102(31), 10858-63 (2005) (Pubitemid 41105957)
47. A. Kawashima, T. Harada, H. Kami, T. Yano, K. Imada and K. Mizuguchi: Effects of eicosapentaenoic acid on synaptic plasticity, fatty acid profile and phosphoinositide 3-kinase signaling in rat hippocampus and differentiated PC12 cells. J Nutr Biochem (2009)
48. J. B. Wan, L. L. Huang, R. Rong, R. Tan, J. Wang and J. X. Kang: Endogenously Decreasing Tissue n-6/n-3 Fatty Acid Ratio Reduces Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice by Inhibiting Systemic and Vascular Inflammation. Arterioscler Thromb Vasc Biol (2010)
49. G. Schmitz and J. Ecker: The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res, 47(2), 147-55 (2008)
50. P. C. Calder: Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res, 52(8), 885-97 (2008)
51. C. Sales, F. Oliviero and P. Spinella: [Fish oil supplementation in rheumatoid arthritis]. Reumatismo, 60(3), 174-9 (2008)
52. K. B. Shah, M. K. Duda, K. M. O'Shea, G. C. Sparagna, D. J. Chess, R. J. Khairallah, I. Robillard-Frayne, W. Xu, R. C. Murphy, C. Des Rosiers and W. C. Stanley: The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: role of cardiac phospholipid remodeling. Hypertension, 54(3), 605-11 (2009)
53. C. J. Lavie, R. V. Milani, M. R. Mehra and H. O. Ventura: Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol, 54(7), 585-94 (2009)
54. O. A. Ozen, M. Cosar, O. Sahin, H. Fidan, O. Eser, H. Mollaoglu, O. Alkoc, M. Yaman and A. Songur: The protective effect of fish n-3 fatty acids on cerebral ischemia in rat prefrontal cortex. Neurol Sci, 29(3), 147-52 (2008) (Pubitemid 352003649)
55. H. C. Pan, T. K. Kao, Y. C. Ou, D. Y. Yang, Y. J. Yen, C. C. Wang, Y. H. Chuang, S. L. Liao, S. L. Raung, C. W. Wu, A. N. Chiang and C. J. Chen: Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J Nutr Biochem, 20(9), 715-25 (2009)
56. V. De Smedt-Peyrusse, F. Sargueil, A. Moranis, H. Harizi, S. Mongrand and S. Laye: Docosahexaenoic acid prevents lipopolysaccharide-induced cytokine production in microglial cells by inhibiting lipopolysaccharide receptor presentation but not its membrane subdomain localization. J Neurochem, 105(2), 296-307 (2008) (Pubitemid 351490003)
57. I. A. Butovich, M. Hamberg and O. Radmark: Novel oxylipins formed from docosahexaenoic acid by potato lipoxygenase-10(S)-hydroxydocosahexaenoic acid and 10,20-dihydroxydocosahexaenoic acid. Lipids, 40(3), 249-57 (2005) (Pubitemid 40628262)
58. P. K. Mukherjee, V. L. Marcheselli, C. N. Serhan and N. G. Bazan: Neuroprotectin D1: a docosahexaenoic acidderived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A, 101(22), 8491-6 (2004) (Pubitemid 38736602)
59. J. M. Schwab, N. Chiang, M. Arita and C. N. Serhan: Resolvin E1 and protectin D1 activate inflammationresolution programmes. Nature, 447(7146), 869-74 (2007) (Pubitemid 46920139)
60. C. N. Serhan, S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick and R. L. Moussignac: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med, 196(8), 1025-37 (2002) (Pubitemid 35231761)
61. H. Hasturk, A. Kantarci, T. Ohira, M. Arita, N. Ebrahimi, N. Chiang, N. A. Petasis, B. D. Levy, C. N. Serhan and T. E. Van Dyke: RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J, 20(2), 401-3 (2006) (Pubitemid 46671185)
62. M. Arita, F. Bianchini, J. Aliberti, A. Sher, N. Chiang, S. Hong, R. Yang, N. A. Petasis and C. N. Serhan: Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med, 201(5), 713-22 (2005) (Pubitemid 40395117)
63. S. Hong, Y. Lu, R. Yang, K. H. Gotlinger, N. A. Petasis and C. N. Serhan: Resolvin D1, protectin D1, and related docosahexaenoic acid-derived products: Analysis via electrospray/low energy tandem mass spectrometry based on spectra and fragmentation mechanisms. J Am Soc Mass Spectrom, 18(1), 128-44 (2007) (Pubitemid 46043440)
64. V. L. Marcheselli, S. Hong, W. J. Lukiw, X. H. Tian, K. Gronert, A. Musto, M. Hardy, J. M. Gimenez, N. Chiang, C. N. Serhan and N. G. Bazan: Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem, 278(44), 43807-17 (2003) (Pubitemid 37346009)
65. C. Boudrault, R. P. Bazinet, J. X. Kang and D. W. Ma: Cyclooxygenase-2 and n-6 PUFA are lower and DHA is higher in the cortex of fat-1 mice. Neurochem Int (2010)
66. I. Khodadadi, B. Griffin and A. Thumser: Differential effects of long-chain fatty acids and clofibrate on gene expression profiles in cardiomyocytes. Arch Iran Med, 11(1), 42-9 (2008) (Pubitemid 351233549)
67. M. Di Nunzio, F. Danesi and A. Bordoni: n-3 PUFA as regulators of cardiac gene transcription: a new link between PPAR activation and fatty acid composition. Lipids, 44(12), 1073-9 (2009)
68. L. G. Puskas, E. Bereczki, M. Santha, L. Vigh, G. Csanadi, F. Spener, P. Ferdinandy, A. Onochy and K. Kitajka: Cholesterol and cholesterol plus DHA diet-induced gene expression and fatty acid changes in mouse eye and brain. Biochimie, 86(11), 817-24 (2004) (Pubitemid 39602761)
69. A. Stahl, P. Sapieha, K. M. Connor, J. P. Sangiovanni, J. Chen, C. M. Aderman, K. L. Willett, N. M. Krah, R. J. Dennison, M. R. Seaward, K. I. Guerin, J. Hua and L. E. Smith: Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res, 107(4), 495-500 (2010)
70. F. Biscetti, E. Gaetani, A. Flex, T. Aprahamian, T. Hopkins, G. Straface, G. Pecorini, E. Stigliano, R. C. Smith, F. Angelini, J. J. Castellot, Jr. and R. Pola: Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes, 57(5), 1394-404 (2008)
71. M. Collino, M. Aragno, R. Mastrocola, M. Gallicchio, A. C. Rosa, C. Dianzani, O. Danni, C. Thiemermann and R. Fantozzi: Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol, 530(1-2), 70-80 (2006) (Pubitemid 43037126)
72. T. Glatz, I. Stock, M. Nguyen-Ngoc, P. Gohlke, T. Herdegen, J. Culman and Y. Zhao: Peroxisome-proliferatoractivated receptors gamma and peroxisome-proliferatoractivated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. J Hypertens (2010)
73. X. Zhao, R. Strong, J. Zhang, G. Sun, J. Z. Tsien, Z. Cui, J. C. Grotta and J. Aronowski: Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci, 29(19), 6186-95 (2009)
74. D. J. Selkoe: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev, 81(2), 741-66 (2001) (Pubitemid 32267077)
75. J. A. Conquer, M. C. Tierney, J. Zecevic, W. J. Bettger and R. H. Fisher: Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids, 35(12), 1305-12 (2000) (Pubitemid 32064179)
76. W. E. Connor, M. Neuringer and D. S. Lin: Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J Lipid Res, 31(2), 237-47 (1990) (Pubitemid 20089038)
77. H. Suzuki, S. J. Park, M. Tamura and S. Ando: Effect of the long-term feeding of dietary lipids on the learning ability, fatty acid composition of brain stem phospholipids and synaptic membrane fluidity in adult mice: a comparison of sardine oil diet with palm oil diet. Mech Ageing Dev, 101(1-2), 119-28 (1998) (Pubitemid 28165639)
78. J. Catalan, T. Moriguchi, B. Slotnick, M. Murthy, R. S. Greiner and N. Salem, Jr.: Cognitive deficits in docosahexaenoic acid-deficient rats. Behav Neurosci, 116(6), 1022-31 (2002) (Pubitemid 35429637)
79. T. J. Montine, M. D. Neely, J. F. Quinn, M. F. Beal, W. R. Markesbery, L. J. Roberts and J. D. Morrow: Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med, 33(5), 620-6 (2002) (Pubitemid 35245834)
80. S. Kalmijn, L. J. Launer, A. Ott, J. C. Witteman, A. Hofman and M. M. Breteler: Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol, 42(5), 776-82 (1997) (Pubitemid 27481550)
81. M. C. Morris, D. A. Evans, J. L. Bienias, C. C. Tangney, D. A. Bennett, R. S. Wilson, N. Aggarwal and J. Schneider: Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol, 60(7), 940-6 (2003) (Pubitemid 36858352)
82. M. R. Prasad, M. A. Lovell, M. Yatin, H. Dhillon and W. R. Markesbery: Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res, 23(1), 81-8 (1998) (Pubitemid 28145695)
83. J. Nourooz-Zadeh, E. H. Liu, B. Yhlen, E. E. Anggard and B. Halliwell: F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem, 72(2), 734-40 (1999) (Pubitemid 29055237)
84. M. Soderberg, C. Edlund, K. Kristensson and G. Dallner: Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids, 26(6), 421-5 (1991)
85. H. R. Wiedemann: William McKim Marriott (1885- 1936). Eur J Pediatr, 152(4), 285 (1993)
86. J. Hardy and D. J. Selkoe: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297(5580), 353-6 (2002) (Pubitemid 34790756)
87. C. Sahlin, F. E. Pettersson, L. N. Nilsson, L. Lannfelt and A. S. Johansson: Docosahexaenoic acid stimulates nonamyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. Eur J Neurosci, 26(4), 882-9 (2007) (Pubitemid 47274614)
88. G. P. Lim, F. Calon, T. Morihara, F. Yang, B. Teter, O. Ubeda, N. Salem, Jr., S. A. Frautschy and G. M. Cole: A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci, 25(12), 3032-40 (2005) (Pubitemid 40463537)
89. K. N. Green, H. Martinez-Coria, H. Khashwji, E. B. Hall, K. A. Yurko-Mauro, L. Ellis and F. M. LaFerla: Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci, 27(16), 4385-95 (2007) (Pubitemid 46640724)
90. R. Ehehalt, P. Keller, C. Haass, C. Thiele and K. Simons: Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol, 160(1), 113-23 (2003) (Pubitemid 36091721)
91. B. Wolozin: Cholesterol and the biology of Alzheimer's disease. Neuron, 41(1), 7-10 (2004) (Pubitemid 38068431)
92. S. Wahrle, P. Das, A. C. Nyborg, C. McLendon, M. Shoji, T. Kawarabayashi, L. H. Younkin, S. G. Younkin and T. E. Golde: Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis, 9(1), 11-23 (2002) (Pubitemid 34174561)
93. D. R. Riddell, G. Christie, I. Hussain and C. Dingwall: Compartmentalization of beta-secretase (Asp2) into lowbuoyant density, noncaveolar lipid rafts. Curr Biol, 11(16), 1288-93 (2001) (Pubitemid 32774087)
94. T. Kawarabayashi, M. Shoji, L. H. Younkin, L. Wen-Lang, D. W. Dickson, T. Murakami, E. Matsubara, K. Abe, K. H. Ashe and S. G. Younkin: Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci, 24(15), 3801-9 (2004) (Pubitemid 38509410)
95. E. Kojro, G. Gimpl, S. Lammich, W. Marz and F. Fahrenholz: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci U S A, 98(10), 5815-20 (2001) (Pubitemid 32435725)
96. M. Simons, P. Keller, B. De Strooper, K. Beyreuther, C. G. Dotti and K. Simons: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A, 95(11), 6460-4 (1998) (Pubitemid 28249035)
97. V. Martin, N. Fabelo, G. Santpere, B. Puig, R. Marin, I. Ferrer and M. Diaz: Lipid Alterations in Lipid Rafts from Alzheimer's Disease Human Brain Cortex. J Alzheimers Dis (2009)
98. V. Martin, N. Fabelo, G. Santpere, B. Puig, R. Marin, I. Ferrer and M. Diaz: Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis, 19(2), 489-502 (2010)
99. R. A. Johnson, J. A. Hamilton, T. S. Worgall and R. J. Deckelbaum: Free fatty acids modulate intermembrane trafficking of cholesterol by increasing lipid mobilities: novel 13C NMR analyses of free cholesterol partitioning. Biochemistry, 42(6), 1637-45 (2003) (Pubitemid 36205971)
100. M. Hashimoto, S. Hossain, H. Agdul and O. Shido: Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta, 1738(1-3), 91-8 (2005) (Pubitemid 43122134)
101. B. Wolozin, W. Kellman, P. Ruosseau, G. G. Celesia and G. Siegel: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch Neurol, 57(10), 1439-43 (2000)
102. I. Casserly and E. Topol: Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet, 363(9415), 1139-46 (2004) (Pubitemid 38452789)
103. M. Hashimoto, H. M. Shahdat, S. Yamashita, M. Katakura, Y. Tanabe, H. Fujiwara, S. Gamoh, T. Miyazawa, H. Arai, T. Shimada and O. Shido: Docosahexaenoic acid disrupts in vitro amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats. J Neurochem, 107(6), 1634-46 (2008)
104. A. Phivilay, C. Julien, C. Tremblay, L. Berthiaume, P. Julien, Y. Giguere and F. Calon: High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease. Neuroscience, 159(1), 296-307 (2009)
105. L. C. Serpell, C. C. Blake and P. E. Fraser: Molecular structure of a fibrillar Alzheimer's A beta fragment. Biochemistry, 39(43), 13269-75 (2000) doi:bi000637v [pii]
106. F. M. LaFerla, K. N. Green and S. Oddo: Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci, 8(7), 499-509 (2007)
107. P. Seubert, C. Vigo-Pelfrey, F. Esch, M. Lee, H. Dovey, D. Davis, S. Sinha, M. Schlossmacher, J. Whaley, C. Swindlehurst and et al.: Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature, 359(6393), 325-7 (1992)
108. C. Haass, M. G. Schlossmacher, A. Y. Hung, C. Vigo-Pelfrey, A. Mellon, B. L. Ostaszewski, I. Lieberburg, E. H. Koo, D. Schenk, D. B. Teplow and et al.: Amyloid betapeptide is produced by cultured cells during normal metabolism. Nature, 359(6393), 322-5 (1992)
109. T. Iwatsubo, A. Odaka, N. Suzuki, H. Mizusawa, N. Nukina and Y. Ihara: Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron, 13(1), 45-53 (1994)
110. G. Bitan, M. D. Kirkitadze, A. Lomakin, S. S. Vollers, G. B. Benedek and D. B. Teplow: Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A, 100(1), 330-5 (2003) (Pubitemid 36078074)
111. M. Hashimoto, H. M. Shahdat, M. Katakura, Y. Tanabe, S. Gamoh, K. Miwa, T. Shimada and O. Shido: Effects of docosahexaenoic acid on in vitro amyloid beta peptide 25-35 fibrillation. Biochim Biophys Acta, 1791(4), 289-96 (2009)
112. J. Busciglio, A. Lorenzo, J. Yeh and B. A. Yankner: beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron, 14(4), 879-88 (1995)
113. M. Shoji, N. Iwakami, S. Takeuchi, M. Waragai, M. Suzuki, I. Kanazawa, C. F. Lippa, S. Ono and H. Okazawa: JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res Mol Brain Res, 85(1-2), 221-33 (2000) (Pubitemid 32056254)
114. Q. L. Ma, F. Yang, E. R. Rosario, O. J. Ubeda, W. Beech, D. J. Gant, P. P. Chen, B. Hudspeth, C. Chen, Y. Zhao, H. V. Vinters, S. A. Frautschy and G. M. Cole: Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci, 29(28), 9078-89 (2009)
115. V. Aguirre, E. D. Werner, J. Giraud, Y. H. Lee, S. E. Shoelson and M. F. White: Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem, 277(2), 1531-7 (2002) (Pubitemid 34968910)
116. B. Giovannone, M. L. Scaldaferri, M. Federici, O. Porzio, D. Lauro, A. Fusco, P. Sbraccia, P. Borboni, R. Lauro and G. Sesti: Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab Res Rev, 16(6), 434-41 (2000) (Pubitemid 32066549)
117. X. J. Sun, J. L. Goldberg, L. Y. Qiao and J. J. Mitchell: Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. Diabetes, 48(7), 1359-64 (1999) (Pubitemid 29297296)
118. E. Steen, B. M. Terry, E. J. Rivera, J. L. Cannon, T. R. Neely, R. Tavares, X. J. Xu, J. R. Wands and S. M. de la Monte: Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis, 7(1), 63-80 (2005) (Pubitemid 40387185)
119. A. M. Moloney, R. J. Griffin, S. Timmons, R. O'Connor, R. Ravid and C. O'Neill: Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging, 31(2), 224-43 (2010)
120. E. J. Rivera, A. Goldin, N. Fulmer, R. Tavares, J. R. Wands and S. M. de la Monte: Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis, 8(3), 247-68 (2005)
121. J. Zhang, Y. Wang, L. Meng, C. Wang, W. Zhao, J. Chen, K. Ghebremeskel and M. A. Crawford: Maternal and neonatal plasma n-3 and n-6 fatty acids of pregnant women and neonates in three regions in China with contrasting dietary patterns. Asia Pac J Clin Nutr, 18(3), 377-88 (2009)
122. M. J. Savage, Y. G. Lin, J. R. Ciallella, D. G. Flood and R. W. Scott: Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci, 22(9), 3376-85 (2002) (Pubitemid 37465743)
123. X. J. Sun, D. L. Crimmins, M. G. Myers, Jr., M. Miralpeix and M. F. White: Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol Cell Biol, 13(12), 7418-28 (1993) (Pubitemid 23354266)
124. K. Lam, C. L. Carpenter, N. B. Ruderman, J. C. Friel and K. L. Kelly: The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin. J Biol Chem, 269(32), 20648-52 (1994)
125. H. Dudek, S. R. Datta, T. F. Franke, M. J. Birnbaum, R. Yao, G. M. Cooper, R. A. Segal, D. R. Kaplan and M. E. Greenberg: Regulation of neuronal survival by the serinethreonine protein kinase Akt. Science, 275(5300), 661-5 (1997) (Pubitemid 27061332)
126. J. S. Song and S. D. Yang: Tau protein kinase I/GSK-3 beta/kinase FA in heparin phosphorylates tau on Ser199, Thr231, Ser235, Ser262, Ser369, and Ser400 sites phosphorylated in Alzheimer disease brain. J Protein Chem, 14(2), 95-105 (1995)
127. J. J. Lucas, F. Hernandez, P. Gomez-Ramos, M. A. Moran, R. Hen and J. Avila: Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J, 20(1-2), 27-39 (2001) (Pubitemid 32099099)
128. K. Leroy, A. Boutajangout, M. Authelet, J. R. Woodgett, B. H. Anderton and J. P. Brion: The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol, 103(2), 91-9 (2002) (Pubitemid 36067485)
129. S. F. Mulot, K. Hughes, J. R. Woodgett, B. H. Anderton and D. P. Hanger: Phosphorylation of tau by glycogen synthase kinase-3 beta in vitro produces species with similar electrophoretic and immunogenic properties to PHF-tau from Alzheimer's disease brain. Biochem Soc Trans, 23(1), 45S (1995)
130. C. J. Phiel, C. A. Wilson, V. M. Lee and P. S. Klein: GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 423(6938), 435-9 (2003) (Pubitemid 36626994)
131. F. Hernandez, J. Borrell, C. Guaza, J. Avila and J. J. Lucas: Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem, 83(6), 1529-33 (2002) (Pubitemid 35477491)
132. S. H. Koh, M. Y. Noh and S. H. Kim: Amyloid-betainduced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res, 1188, 254-62 (2008) (Pubitemid 350296066)
133. A. Takashima, K. Noguchi, G. Michel, M. Mercken, M. Hoshi, K. Ishiguro and K. Imahori: Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci Lett, 203(1), 33-6 (1996)
134. D. Terwel, D. Muyllaert, I. Dewachter, P. Borghgraef, S. Croes, H. Devijver and F. Van Leuven: Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol, 172(3), 786-98 (2008) (Pubitemid 351354550)
135. S. S. Bandaru, K. Lin, S. L. Roming, R. Vellipuram and J. P. Harney: Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior. Physiol Behav (2009)
136. R. D. Terry, E. Masliah, D. P. Salmon, N. Butters, R. DeTeresa, R. Hill, L. A. Hansen and R. Katzman: Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol, 30(4), 572-80 (1991)
137. D. Z. Christensen, T. A. Bayer and O. Wirths: Intracellular Abeta triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging (2008)
138. P. J. Whitehouse, D. L. Price, R. G. Struble, A. W. Clark, J. T. Coyle and M. R. Delon: Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 215(4537), 1237-9 (1982) (Pubitemid 12106486)
139. S. Aid, S. Vancassel, C. Poumes-Ballihaut, S. Chalon, P. Guesnet and M. Lavialle: Effect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat hippocampus. J Lipid Res, 44(8), 1545-51 (2003) (Pubitemid 37279599)
140. F. Calon, G. P. Lim, F. Yang, T. Morihara, B. Teter, O. Ubeda, P. Rostaing, A. Triller, N. Salem, Jr., K. H. Ashe, S. A. Frautschy and G. M. Cole: Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron, 43(5), 633-45 (2004) (Pubitemid 39179724)
141. M. Hashimoto, S. Hossain, T. Shimada, K. Sugioka, H. Yamasaki, Y. Fujii, Y. Ishibashi, J. Oka and O. Shido: Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem, 81(5), 1084-91 (2002) (Pubitemid 34809291)
142. T. J. Montine and J. D. Morrow: Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am J Pathol, 166(5), 1283-9 (2005) (Pubitemid 40586500)
143. K. S. Montine, J. F. Quinn, J. Zhang, J. P. Fessel, L. J. Roberts, 2nd, J. D. Morrow and T. J. Montine: Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids, 128(1-2), 117-24 (2004) (Pubitemid 38167381)
144. M. Hashimoto, Y. Tanabe, Y. Fujii, T. Kikuta, H. Shibata and O. Shido: Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr, 135(3), 549-55 (2005) (Pubitemid 40365217)
145. W. J. Lukiw, J. G. Cui, V. L. Marcheselli, M. Bodker, A. Botkjaer, K. Gotlinger, C. N. Serhan and N. G. Bazan: A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest, 115(10), 2774-83 (2005) (Pubitemid 41434404)
146. N. G. Bazan: Neuroprotectin D1 (NPD1): a DHAderived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol, 15(2), 159-66 (2005) (Pubitemid 40546172)
147. I. Vedin, T. Cederholm, Y. Freund Levi, H. Basun, A. Garlind, G. Faxen Irving, M. E. Jonhagen, B. Vessby, L. O. Wahlund and J. Palmblad: Effects of docosahexaenoic acidrich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr, 87(6), 1616-22 (2008) (Pubitemid 351872622)
148. G. M. Cole, G. P. Lim, F. Yang, B. Teter, A. Begum, Q. Ma, M. E. Harris-White and S. A. Frautschy: Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic antioxidant interventions. Neurobiol Aging, 26 Suppl 1, 133-6 (2005)
149. A. Kawashima, T. Harada, K. Imada, T. Yano and K. Mizuguchi: Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta- stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma. Prostaglandins Leukot Essent Fatty Acids, 79(1-2), 59-65 (2008)
150. P. Taepavarapruk and C. Song: Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1beta administrations: effects of omega-3 fatty acid EPA treatment. J Neurochem, 112(4), 1054-64 (2010)
151. G. M. Cole, Q. L. Ma and S. A. Frautschy: Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids, 81(2-3), 213-21 (2009)
152. R. Bene, S. Antic, M. Budisic, M. Lisak, Z. Trkanjec, V. Demarin and S. Podobnik-Sarkanji: Parkinson's disease. Acta Clin Croat, 48(3), 377-80 (2009)
153. H. Chen, S. M. Zhang, M. A. Hernan, W. C. Willett and A. Ascherio: Dietary intakes of fat and risk of Parkinson's disease. Am J Epidemiol, 157(11), 1007-14 (2003) (Pubitemid 36628804)
154. K. M. Powers, T. Smith-Weller, G. M. Franklin, W. T. Longstreth, Jr., P. D. Swanson and H. Checkoway: Dietary fats, cholesterol and iron as risk factors for Parkinson's disease. Parkinsonism Relat Disord, 15(1), 47-52 (2009)
155. L. M. de Lau, M. Bornebroek, J. C. Witteman, A. Hofman, P. J. Koudstaal and M. M. Breteler: Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology, 64(12), 2040-5 (2005) (Pubitemid 40880989)
156. M. Bousquet, M. Saint-Pierre, C. Julien, N. Salem, Jr., F. Cicchetti and F. Calon: Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J, 22(4), 1213-25 (2008) (Pubitemid 351519975)
157. P. Samadi, L. Gregoire, C. Rouillard, P. J. Bedard, T. Di Paolo and D. Levesque: Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol, 59(2), 282-8 (2006) (Pubitemid 43202481)
158. H. Kabuto, M. Amakawa, M. Mankura, T. T. Yamanushi and A. Mori: Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Neurochem Res, 34(7), 1299-303 (2009)
159. R. Sharon, I. Bar-Joseph, G. E. Mirick, C. N. Serhan and D. J. Selkoe: Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem, 278(50), 49874-81 (2003) (Pubitemid 37548822)
160. E. Dalfo, M. Portero-Otin, V. Ayala, A. Martinez, R. Pamplona and I. Ferrer: Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol, 64(9), 816-30 (2005) (Pubitemid 41285815)
161. M. L. Selley: (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med, 25(2), 169-74 (1998) (Pubitemid 28293150)
162. A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E. R. Stadtman and Y. Mizuno: Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A, 93(7), 2696-701 (1996) (Pubitemid 26114311)
163. D. T. Dexter, C. J. Carter, F. R. Wells, F. Javoy-Agid, Y. Agid, A. Lees, P. Jenner and C. D. Marsden: Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem, 52(2), 381-9 (1989) (Pubitemid 19037600)
164. M. G. Spillantini, R. A. Crowther, R. Jakes, M. Hasegawa and M. Goedert: alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A, 95(11), 6469-73 (1998) (Pubitemid 28249037)
165. J. M. Souza, B. I. Giasson, V. M. Lee and H. Ischiropoulos: Chaperone-like activity of synucleins. FEBS Lett, 474(1), 116-9 (2000) (Pubitemid 30320843)
166. A. Abeliovich, Y. Schmitz, I. Farinas, D. Choi-Lundberg, W. H. Ho, P. E. Castillo, N. Shinsky, J. M. Verdugo, M. Armanini, A. Ryan, M. Hynes, H. Phillips, D. Sulzer and A. Rosenthal: Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25(1), 239-52 (2000) (Pubitemid 30316525)
167. J. M. George, H. Jin, W. S. Woods and D. F. Clayton: Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron, 15(2), 361-72 (1995)
168. K. Assayag, E. Yakunin, V. Loeb, D. J. Selkoe and R. Sharon: Polyunsaturated fatty acids induce alpha-synucleinrelated pathogenic changes in neuronal cells. Am J Pathol, 171(6), 2000-11 (2007)
169. K. Broersen, D. van den Brink, G. Fraser, M. Goedert and B. Davletov: Alpha-synuclein adopts an alpha-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation. Biochemistry, 45(51), 15610-6 (2006) (Pubitemid 46032482)
170. X. Liu, N. Yamada, W. Maruyama and T. Osawa: Formation of dopamine adducts derived from brain polyunsaturated fatty acids: mechanism for Parkinson disease. J Biol Chem, 283(50), 34887-95 (2008)
171. Q. Meng, D. W. Luchtman, B. El Bahh, J. A. Zidichouski, J. Yang and C. Song: Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices. Eur J Pharmacol (2010)